Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1715 - Real-World Outcomes Following Pemivibart (Pemgarda™) for COVID-19 Prophylaxis in Immunocompromised Patients with Hematologic Malignancies

    Primary Author(s)

  • RM

    Rudy Mrad, MD

    UT Southwestern Medical Center
    Dallas, Texas, United States

    • Co-Author / Presenter(s)

  • FA

    Farrukh T. Awan, MD

    Associate Professor and Director of Lymphoid Malignancies Program at UTSW
    The University of Texas Southwestern
    Dallas, Texas, United States